107 related articles for article (PubMed ID: 1643743)
41. In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging.
Peters RH; Brandon CS; Avila LA; Colvin OM; Stuart RK
Cancer Chemother Pharmacol; 1989; 23(3):129-34. PubMed ID: 2924369
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of human NK cell cytotoxicity against K562 cells with glycopeptides from K562 plasma membranes.
Decker JM; Hinson A; Ades EW
J Clin Lab Immunol; 1984 Nov; 15(3):137-43. PubMed ID: 6397595
[TBL] [Abstract][Full Text] [Related]
43. Functional defects of NK cells treated with chloroquine mimic the lytic defects observed in perforin-deficient mice.
Austin Taylor M; Bennett M; Kumar V; Schatzle JD
J Immunol; 2000 Nov; 165(9):5048-53. PubMed ID: 11046034
[TBL] [Abstract][Full Text] [Related]
44. Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats.
Wiley JM; Yeager AM
Exp Hematol; 1991 Mar; 19(3):179-84. PubMed ID: 1704843
[TBL] [Abstract][Full Text] [Related]
45. Ethanol and natural killer cells. II. Stimulation of human natural killer activity by ethanol in vitro.
Li F; Cook RT; Alber C; Rasmussen W; Stapleton JT; Ballas ZK
Alcohol Clin Exp Res; 1997 Sep; 21(6):981-7. PubMed ID: 9309305
[TBL] [Abstract][Full Text] [Related]
46. Hamster monoclonal antibodies to murine natural killer cells.
Linnemeyer PA; Tsuji JM; Gill S; Pollack SB
Nat Immun; 1994; 13(1):49-60. PubMed ID: 8111193
[TBL] [Abstract][Full Text] [Related]
47. Stimulation of natural killer cell numbers but not function in leukemic infant mice: a system primed in infancy allows survival in adulthood.
Dussault I; Miller SC
Nat Immun; 1993; 12(2):66-78. PubMed ID: 8318817
[TBL] [Abstract][Full Text] [Related]
48. Natural killer cells generated from bone marrow culture.
Koo GC; Peppard JR; Mark WH
J Immunol; 1984 May; 132(5):2300-4. PubMed ID: 6201540
[TBL] [Abstract][Full Text] [Related]
49. A novel approach to immunomodulation of frozen human bone marrow with interleukin-2 for clinical application.
Charak BS; Areman EM; Dickerson SA; Choudhary GD; Sacher R; Kotula PL; Brown EG; Mazumdar A
Bone Marrow Transplant; 1993 Feb; 11(2):147-54. PubMed ID: 8435664
[TBL] [Abstract][Full Text] [Related]
50. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
51. Usefulness of lymphokine-activated killer cells generated from bone marrow mononuclear cells for the purging of residual tumor cells in peripheral blood stem cell graft.
Komatsu F; Kajiwara M
Jpn J Cancer Res; 1996 Feb; 87(2):161-9. PubMed ID: 8609065
[TBL] [Abstract][Full Text] [Related]
52. Effects of in vitro treatment with 4-hydroperoxycyclophosphamide and hyperthermia on leukemic progenitor cells.
Minegishi N; Minegishi M; Tsuchiya S; Konno T
Tohoku J Exp Med; 1989 Oct; 159(2):101-11. PubMed ID: 2609329
[TBL] [Abstract][Full Text] [Related]
53. Regulation of natural killer cell production in bone marrow of mice: no evidence for negative feedback control.
Bilge A; Pollack SB
Nat Immun; 1992; 11(3):156-66. PubMed ID: 1392403
[TBL] [Abstract][Full Text] [Related]
54. Increased natural killer cell activity and numbers of Leu-7 and Leu-11b (CD 16)-positive cells in bone marrow of children in remission from acute lymphoblastic leukaemia.
Sørskaar D; Førre O; Lie SO
Scand J Immunol; 1989 Jan; 29(1):65-72. PubMed ID: 2466327
[TBL] [Abstract][Full Text] [Related]
55. Generation of mouse natural killer (NK) cell activity: effect of interleukin-2 (IL-2) and interferon (IFN) on the in vivo development of natural killer cells from bone marrow (BM) progenitor cells.
Riccardi C; Giampietri A; Migliorati G; Cannarile L; D'Adamio L; Herberman RB
Int J Cancer; 1986 Oct; 38(4):553-62. PubMed ID: 2944847
[TBL] [Abstract][Full Text] [Related]
56. Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide.
Sharkis SJ; Santos GW; Colvin M
Blood; 1980 Mar; 55(3):521-3. PubMed ID: 6986920
[TBL] [Abstract][Full Text] [Related]
57. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
Mumcuoglu M; Naparstek E; Slavin S
Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
[TBL] [Abstract][Full Text] [Related]
58. Natural killer (NK) cell activity in human long-term bone marrow cultures (LTBMC): effects of interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on the progenitor cells.
Sitnicka E; Hansson M
Immunology; 1992 Jun; 76(2):292-8. PubMed ID: 1634251
[TBL] [Abstract][Full Text] [Related]
59. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
60. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation.
Long GS; Hiserodt JC; Harnaha JB; Cramer DV
Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
